Ocular Allergy Management and Treatment Strategies

Ocular allergy encompasses a spectrum of hypersensitivity reactions affecting the conjunctiva and cornea, ranging from common seasonal and perennial allergic conjunctivitis to more severe forms such as vernal keratoconjunctivitis and atopic keratoconjunctivitis. Management strategies have evolved from nonspecific lubricants and systemic antihistamines towards targeted topical therapies and immunomodulatory approaches that address underlying inflammatory pathways. First‐line treatment for mild to moderate disease typically involves preservative‐free antihistamine eye drops and mast cell stabilisers, or dual‐action agents that combine both mechanisms. In cases of persistent or severe inflammation, topical corticosteroids may be employed with caution, balancing efficacy against the risk of ocular hypertension and cataract formation. Calcineurin inhibitors such as cyclosporine and tacrolimus have emerged as steroid-sparing alternatives, reducing T-cell activation and cytokine release. For refractory or vision-threatening disease, biologic agents targeting immunoglobulin E or specific cytokines offer novel therapeutic avenues. An integrated approach that includes identification and avoidance of environmental triggers, optimisation of tear film integrity and patient education underpins long-term control and quality of life. Advances in formulation science, such as sustained-release delivery systems and preservative-free preparations, continue to improve tolerability and adherence, while ongoing research seeks biomarkers to personalise therapy and predict treatment response.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Ocular Allergy Management and Treatment Strategies publication trend

The graph below shows the total number of articles in ocular allergy management and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Seasonal allergic conjunctivitis (SAC): IgE-mediated hypersensitivity reaction of the conjunctiva triggered by seasonal airborne allergens.

Perennial allergic conjunctivitis (PAC): Chronic conjunctival inflammation due to year-round exposure to indoor allergens.

Vernal keratoconjunctivitis (VKC): Severe, chronic ocular allergy with giant papillae formation, often affecting children and young adults.

Mast cell stabiliser: Topical agent that prevents release of histamine and other mediators from mast cells.

Dual-action agent: Ophthalmic preparation combining antihistamine and mast cell stabilising properties.

Omalizumab: Monoclonal antibody directed against immunoglobulin E, used to reduce allergic inflammation in refractory cases.

References

1. A contemporary look at allergic conjunctivitis. Allergy, Asthma & Clinical Immunology (2020).
2. Allergic Conjunctivitis Management: Update on Ophthalmic Solutions. Current Allergy and Asthma Reports (2024).
3. Topical tacrolimus in anterior segment inflammatory disorders. Eye and Vision (2017).
4. Management of vernal keratoconjunctivitis: Navigating a changing treatment landscape. Survey of Ophthalmology (2023).
5. Unraveling the complexity – Insights and interventions of refractory vernal keratoconjunctivitis. The Ocular Surface (2024).
6. Vernal keratoconjunctivitis: Current immunological and clinical evidence and the potential role of omalizumab. World Allergy Organization Journal (2023).
7. Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature. Ophthalmology and Therapy (2016).